Efficacy of Enasidenib and Risk-Adapted Addition of Azacitidine in Patients With Newly Diagnosed IDH2-Mutant AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML
Blood Adv 2023 Oct 23;[EPub Ahead of Print], SF Cai, Y Huang, JR Lance, HCC Mao, A Dunbar, S McNulty, TE Druley, Y Li, MR Baer, W Stock, T Kovacsovics, W Blum, GJ Schiller, RL Olin, JM Foran, MR Litzow, TL Lin, PA Patel, MC Foster, M Boyiadzis, RH Collins, J Chervin, AB Shoben, JA Vergilio, NA Heerema, L Rosenberg, TL Chen, AO Yocum, F Druggan, S Marcus, M Stefanos, BJ Druker, AS Mims, U Borate, A Burd, JC Byrd, RL Levine, EM SteinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.